Theratechnologies Inc. (NasdaqCM: THTX)
Health Care · Biotechnology · CA
$—
— today · — 1Y
Theratechnologies Inc. (NasdaqCM: THTX) operates in the Biotechnology industry within the Health Care sector.
trading between 3.24 and 3.40.
Tweenvest scores Theratechnologies Inc. across four factors: quality 48/100, growth 52/100. Its strongest factor is growth.
THTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $84.38M
- P/E
- —
- EPS
- -0.19
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $3.40
- 52-week low
- $3.24
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 103
- Next earnings
- —
About Theratechnologies Inc.
Theratechnologies Inc. is a biopharmaceutical firm dedicated to creating and marketing a range of treatments aimed at fulfilling critical medical requirements across the United States, Canada, and Europe. Its current product portfolio includes EGRIFTA and EGRIFTA SV, designed to diminish excessive abdominal fat in HIV-positive individuals experiencing lipodystrophy. Additionally, it markets Trogarzo, an injectable formulation of ibalizumab, which targets multidrug-resistant HIV-1 infections. Within its development pipeline are F8 Formulation, intended for addressing lipodystrophy in people with HIV; TH1902, currently undergoing Phase 1/Part A clinical trials for triple-negative breast cancer; and TH1904, aimed at treating ovarian cancer. Established in 1993, the company maintains its main office in Montreal, Canada.
- ISIN
- CA88338H7040
- Founded
- 1993
- Listed since
- Feb 13, 2009
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.